| Business Summary | | Forest
Laboratories,
Inc.
(Forest)
develops,
manufactures
and
sells
both
branded
and
generic
forms
of
ethical
drug
products
that
require
a
physician's
prescription,
as
well
as
non-prescription
pharmaceutical
products
sold
over-the-counter.
The
Company's
most
important
U.S.
products
consist
of
branded
ethical
drug
specialties
marketed
directly,
or
"detailed,"
to
physicians
by
its
Forest
Pharmaceuticals,
Forest
Therapeutics
and
Forest
Specialty
sales
forces.
The
Company's
products
include
those
developed
by
Forest
and
those
acquired
from
other
pharmaceutical
companies
and
integrated
into
Forest's
marketing
and
distribution
systems.
Principal
products
include
Celexa,
Forest's
SSRI
for
the
treatment
of
depression;
the
respiratory
products
Aerobid
and
Aerochamber;
Tiazac,
Forest's
once-daily
diltiazem
for
the
treatment
of
hypertension
and
angina;
and
Infasurf,
a
lung
surfactant
for
the
treatment
and
prevention
of
respiratory
distress
syndrome
in
premature
infants. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | FRX
develops,
manufactures
and
sells
both
branded
and
generic
forms
of
ethical
drug
products
which
require
a
physicians
prescription,
as
well
as
non-prescription
pharmaceutical
products
sold
over-the
counter.
For
the
three
months
ended
6/30/01,
revenues
rose
35%
to
$359.1
million.
Net
income
totaled
$74
million,
up
from
$28.3
million.
Revenues
reflect
increased
sales
of
Celexa
and
Tiazac.
Net
income
also
reflects
improved
plant
utilization
and
product
mix. | More
from
Market Guide: Significant
Developments |
| | | | FY2001
Compensation | | Pay | Exer | |
| Howard Solomon, 73 Chairman
and CEO | $1.2M | $147M | Kenneth Goodman, 53 Pres,
COO | 819K | 32M | John Eggers, 39 CFO,
VP-Fin. | 320K | -- | Lawrence Olanoff, Ph.D., M.D., 49 Exec.
VP-Scientific Affairs | 712K | 13M | Elaine Hochberg, 44 Sr.
VP of Marketing | 524K | -- | Dollar
amounts are as of 31-Mar-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|